GLP-1s: Compounders Get Temporary Reprieve But US FDA May Be Building Stronger Case

 
• By Sarah Karlin-Smith
  
The FDA agreed to reconsider its decision to remove Lilly's GLP-1 drug from the shortage list following a compounder lawsuit. (Shutterstock)

More from Litigation

More from Compliance